Other3

Iambic Therapeutics, Inc.

Total Value

$NaN

Filing Date

Oct 14, 2026

1 transactions

Trade Summary

On Oct 14, 2026, Rachlin Evan Lockwood, Insider, reported $NaN of Iambic Therapeutics, Inc. (IAM) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Rachlin Evan Lockwood
Role: Insider
Location: SAN DIEGO, CA

Filing Details

Filing Date: Oct 14, 2026
Transaction Date: Oct 14, 2026
Accession Number: 0002151678-26-000003
Form Type: 3

Want live alerts when Rachlin Evan Lockwood trades again?

Download Insider Trades to track IAM, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(F2)The shares are held of record by Ascenta Capital Fund I, L.P., or Ascenta Capital Fund I. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Fund I, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Fund I. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
(F3)The shares are held of record by Ascenta Capital Project Turing SPV, L.P., or Ascenta Capital Project Turing. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Project Turing, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Project Turing. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
(F4)Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(F5)The amount of shares reported assumes the Issuer's initial public offering price per share (the "IPO Price") to be $16.00 per share.
(F6)The conversion price is equal to the lower of (i) 85% of the IPO Price (reflecting a 15% discount) and (ii) the price per share implied by a $900.0 million valuation cap.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rachlin Evan Lockwood

(Last)

(First)

(Middle)

C/O IAMBIC THERAPEUTICS, INC.

5627 OBERLIN DRIVE, SUITE 120

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/14/2026

3. Issuer Name and Ticker or Trading Symbol
Iambic Therapeutics, Inc. [ IAM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	1,152,025	⁽¹⁾	I	See footnote⁽²⁾
Series B Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	57,754	⁽¹⁾	I	See footnote⁽³⁾
Series B-3 Convertible Preferred Stock	⁽⁴⁾	⁽⁴⁾	Common Stock	306,711	⁽⁴⁾	I	See footnote⁽²⁾
Convertible Promissory Notes	10/16/2026	08/14/2028	Common Stock	410,762⁽⁵⁾	⁽⁶⁾	I	See footnote⁽²⁾

Explanation of Responses:

1. Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

2. The shares are held of record by Ascenta Capital Fund I, L.P., or Ascenta Capital Fund I. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Fund I, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Fund I. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

3. The shares are held of record by Ascenta Capital Project Turing SPV, L.P., or Ascenta Capital Project Turing. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Project Turing, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Project Turing. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

4. Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

5. The amount of shares reported assumes the Issuer's initial public offering price per share (the "IPO Price") to be $16.00 per share.

6. The conversion price is equal to the lower of (i) 85% of the IPO Price (reflecting a 15% discount) and (ii) the price per share implied by a $900.0 million valuation cap.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Sunny Chang, by power of attorney	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0002151678-26-000003.

Iambic Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when Rachlin Evan Lockwood trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3